Intra Cellular Therapies Inc (ITCI) News

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an...

Form 8-K - Current report

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a...

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities